NEW YORK, March 8, 2005 (PRIMEZONE) -- Amazon Biotech, Inc. (OTCBB:AMZB) today announced the appointment of Kathleen K. Casey, M.D., F.A.C.P., F.I.D.S.A. to its Scientific Advisory Board.
Dr. Casey has over 20 years' experience as an Infectious Disease Specialist. Dr. Casey currently is involved with the A-Team, a medical group affiliated with Jersey Shore University Medical Center that is passionately committed to saving the lives of men, women, and children living in the community by providing them with cutting-edge HIV care from their infectious disease doctors and staff. Casey trained and completed her residency at the University of Medicine and Dentistry N.J. (UMDNJ) - Rutgers. Dr. Casey has also been affiliated with the Robert Wood Johnson Medical School N.J. and with the Jersey Shore University Medical Center. Academically, Dr. Casey has been a full-time professor in the Department of Medicine at UMDNJ - Robert Wood Johnson Medical School (New Brunswick, NJ). Dr. Casey is also the medical director of the Monmouth County TB Clinic (Freehold, NJ) and the Section Chief of the Infectious Disease Section at the Department of Medicine, Jersey Shore University Medical Center (Neptune, NJ). Dr. Casey is a member of numerous medical societies and associations and the recipient of several professional awards.
Dr Chinnici, CEO of Amazon Biotech, said, "I am extremely pleased to welcome Dr. Casey to our Company's Board. Her dedication to health and medicine will be beneficial for shaping the future of Amazon Biotech as a global leader in the fight against HIV/AIDS. Dr. Casey's broad knowledge in infectious diseases and relationship with leading hospitals will significantly enhance the knowledge base of our Board. With her many years of specialized experience in the treatment of AIDS and in the field of infectious disease, Dr. Casey has a deep and thorough understanding of the fundamentals of our treatment approach."
Dr. Casey was quoted as saying, "My colleagues and I are extremely excited and eagerly await the anticipated trail of AMZ0026 sponsored by Amazon Biotech at our ambulatory AIDS Care Center (The A. Team ). I believe our patients will be excited and eager to participate. I am anticipating a very positive response."
About Amazon Biotech, Inc.
Amazon Biotech, Inc. is a natural plant pharmaceutical company, primarily developing immune modulator drugs. AMZ0026 is the Company's first such drug, to be used for the treatment of HIV/AIDS. The company intends to initiate Phase I/II clinical studies of AMZ0026 shortly, with an eventual goal of a joint venture with a major pharmaceutical company in Phase III trials, or follow the FDA Fast Track program to market. Amazon Biotech specializes in natural plant pharmaceutical drugs and is focused on bringing healthier pharmaceutical drugs to market. Additional information on Amazon Biotech may be found at www.amazonbiotech.com.
Forward-Looking Statements
"Safe-Harbor" Statement Under the Private Securities Litigation Reform Act of 1995
This press release contains forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934, including statements regarding any potential sales of products as well as statements that include the words "believes," "expects," "anticipates," or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Amazon Biotech to differ materially from those implied or expressed by such forward-looking statements. Such factors include, among others, the risk factors included in Amazon Biotech's subsequent reports filed with the Securities and Exchange Commission under the Exchange Act. This press release speaks as of the date first set forth above and Amazon Biotech assumes no responsibility to update the information included herein for events occurring after the date hereof.